EP0815206A1 - Cell culture method - Google Patents

Cell culture method

Info

Publication number
EP0815206A1
EP0815206A1 EP96907597A EP96907597A EP0815206A1 EP 0815206 A1 EP0815206 A1 EP 0815206A1 EP 96907597 A EP96907597 A EP 96907597A EP 96907597 A EP96907597 A EP 96907597A EP 0815206 A1 EP0815206 A1 EP 0815206A1
Authority
EP
European Patent Office
Prior art keywords
cells
selectable marker
population
selected sub
sub
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96907597A
Other languages
German (de)
French (fr)
Inventor
Bradley Michael John Stringer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFactors PLC
Original Assignee
CellFactors PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellFactors PLC filed Critical CellFactors PLC
Publication of EP0815206A1 publication Critical patent/EP0815206A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0618Cells of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Definitions

  • the present invention relates to cell culture methods, and in particular to cell culture methods for the production of an essentially homogeneous population of cells (for example neuronal cells) in vitro.
  • the invention also relates to neural cells (e.g. human neural cells) having introduced therein a selectable marker (e.g. a positive and/or negative selectable marker) .
  • a selectable marker e.g. a positive and/or negative selectable marker
  • the central nervous sytem is presently the subject of intense research, but its enormous complexity at the cellular level has militated against a full understanding of its function. While increasingly selective methods of labelling specific sub-populations of neural cells ex vivo (such as immunostaining, in situ hybridization histochemistry etc.) have been developed, the separation and purification of such sub-populations as living cells presents severe difficulties.
  • FACS fluorescence-activated cell sorting
  • Another method is based upon the identification of extracellular membrane-bound markers specific for a given cell type (Urakami & Chiu (1990) J. Neuroscience 10:620).
  • separation in this example is achieved by panning the mixed cell population on an adherent antibody layer to produce cell-antibody complexes from which the cells of interest can later be dissociated for further study.
  • progenitor cells which give rise to specific cell populations are immortalized by oncogene transduction or by the sub-culturing of spontaneous cell outgrowths.
  • the degree of purification required to obtain homogeneity is often two or more orders of magnitude: such an enrichment is too great for FACS or panning, the result being a degree of contamination.
  • the present invention provides a method for selectively culturing a pre-selected sub-population of cells from a heterogenous population in vitro, comprising the steps of: (a) introducing a selectable marker (e.g. a positive and/or negative selectable marker) into the heterogenous cell population, which marker is subject to differential expression/activity in the pre-selected sub-population; and (b) selectively culturing the pre-selected sub-population on the basis of the differential expression/activity therein of the selectable marker.
  • a selectable marker e.g. a positive and/or negative selectable marker
  • the pre-selected sub-population of cells may be an essentially homogeneous population of cells of a particular cell type or cell class.
  • the pre-selected sub-population may be a particular class of neural cells.
  • the pre-selected population may be selected on the basis of transmitter characteristics, e.g. dopamine- or acetylcholine-containing neurones may be selectively cultured according to the method of the invention.
  • the selectable marker need not be introduced into every cell making up the heterogenous cell population: for most purposes it is sufficient if a significant proportion of the cells receive the selectable marker.
  • the selectable marker(s) are introduced into a large proportion (for example essentially all) of the heterogenous cell population.
  • the method of the invention finds particular application in the selective culture of particular classes of essentially normal neural cells.
  • the method of the present invention is of general application and may be used to selectively culture other sub-populations of cells.
  • mammalian neural cells can be transduced with heterologous genetic material. Many methods exist for transducing eukaryotic and other cells, but the characteristics of neural cells are such that natural methods of transfection are presently the most useful (Miller (1992) Nature 357:455). Thus, transduction with virally-packaged genetic material, for example, is not only more efficient, but also results in a lower neural cell mortality during the actual process than does, for example, calcium phosphate precipitation, electroporation, microprojectile bombardment or microinjection. Transduction of mammalian neural cells from the central nervous system both in vivo (Culver et al. (1992) Science 256:1550) and in vitro (Stringer & Foster (1994) Brain Res 79:267) has been described.
  • the genetic material that can be introduced into living cells may include both positive and negative selectable markers.
  • a positive selectable marker is one that permits survival of the transduced cell under conditions which would kill cells not expressing the selectable phenotype.
  • a negative selectable marker confers sensitivity on the cells which express it, such that they are destroyed under conditions which are relatively innocuous to other cells.
  • Genes that are widely applied as positive selectable markers include the bacterial neomycin phosphotransferase (neo; Colbere-Garapin et al. (1981) J. Mol. Biol. 150:1), hygromycin phosphotransferase (hph; Santerre et al. (1984) Gene 30:147) and xanthineguanine phosphoribosyl transferase (gpt; Mulligan & Berg (1981) Proc. Natl. Acad. Sci. USA 78:2072).
  • HSV-1 TK herpes simplex virus type 1 thymidine kinase
  • APRT adenine phosphoribosyl transferase
  • HPRT hypoxanthine phosphoribosyl transferase
  • Preferred negative selectable markers include genes encoding products involved in programmed cell death (apoptosis), for example the gene for p53. Such negative selectable markers may be activated by inducing the expression of the gene in question (for example by use of a tetracycline-responsive promoter, as described infra) .
  • the use of genes encoding products involved in apoptosis has the advantage that transient expression (in many cases 30 minutes or less) of the gene may be sufficient to commit the cell to death, permitting reliable and very stringent negative selection.
  • Some of the aforementioned genes also confer negative as well as positive selectable phenotypes. They include the HSV-1, APRT, HPRT and gpt genes. These genes encode enzymes which can catalyze the conversion of certain nucleoside or purine analogues to cytotoxic intermediates.
  • the nucleoside analogue ganciclovir GCV
  • GCV nucleoside analogue ganciclovir
  • Xanthineguanine phosphoribosyl transferase can be used for both positive and negative selection which expressed in wild type cells (Besnard et al. (1987) Mol. Cell Biol. 7:4139). Cytosine deaminase can also be used as a negative selection marker, converting the innocuous 5-fluorocytosine to the cytotoxic 5-fluorouracil (Polak & Scholer (1976) Chemotherapy (Basel) 21:113).
  • Selectable markers are usually used in both prokaryotic and eukaryotic genetic engineering to permit the recovery from a mixed population of cells those which have undergone a rare genetic change. For instance, they can be used in physical association with another gene which encodes a product of interest to select cells which have taken up that other gene along with the selectable marker. As an example, the neo gene has been used to monitor genetically modified cells taken from patient samples after gene therapy has taken place.
  • the method of the invention can include the prior induction of replication in mixed populations of embryonic neural cells, using supplements to the culture medium such as epidermal growth factor or fibroblast growth factor, or by prior transfection with immortalizing oncogenes, to elicit such replication.
  • non-expanding cell cultures can be used.
  • the cells are transduced with a positive selectable marker and a negative selectable marker, both linked operably to an expression element.
  • the expression element may be specific for a given central nervous system region, a given neural cell type, or a specific sub-population of neurones.
  • the cells may be allowed, at least partially, to differentiate.
  • the appropriate drug can then be applied, such that non- transduced cells and those transduced cells without the active specific expression element are eliminated, while transduced cells with the active element (which leads to the expression of the downstream selectable markers) will be resistant.
  • the expression elements for use in the invention may be selected from: promoters and/or enhancers which are specifically active in: (i) dopaminergic, serotoninergic, GABAergic, cholinergic or peptidergic neurones, or sub-populations thereof; (ii) Schwann cells, oligodendrocytes, astroycytes, microglia and sub-populations thereof; (iii) particular stages of embryogenesis and (iv) other specific non-neural tissues.
  • promoters and/or enhancers which are specifically active in: (i) dopaminergic, serotoninergic, GABAergic, cholinergic or peptidergic neurones, or sub-populations thereof; (ii) Schwann cells, oligodendrocytes, astroycytes, microglia and sub-populations thereof; (iii) particular stages of embryogenesis and (iv) other specific non-neural tissues.
  • Particularly preferred for use in the present invention
  • promoters and/or enhancers which direct the transcription of genes for: (i) neurotransmitter-specific receptors; (ii) ion channels; (iii) receptors involved in ion-channel gating, (iv) cytokines, growth factors and hormones and (v) any substance that is specifically produced and secreted in a paracrine, autocrine or endocrine fashion.
  • the invention provides a method of culturing human and other mammalian cells (e.g. neural cells) and, by selecting for a sub-population of cells on the basis of the genetic material contained within them, producing homogeneous cultures of a single cell type.
  • mammalian cells e.g. neural cells
  • Such cultures can be put to a variety of uses including basic electrophysiological, neurochemical and developmental experimentation.
  • the purified neural cell populations will be useful in more clinically applied studies, such as assessment of the feasibility of transplantation to alleviate the symptoms of central nervous sytem degenerative disease, and find application in various forms of therapy, prophylaxis and diagnosis.
  • Such diseases include: (i) Parkinson's disease or parkinsonism, the pre-selected sub-population of cells being dopaminergic neurones of the substantia nigra; (ii) Huntington's disease, the pre-selected sub-population of cells being neural cells of the striatum; (iii) Alzheimer's disease, the pre-selected sub-populations of cells being acetylcholine-, serotonin-, and/or noradrenaline-containing neurones associated with the neo- and palaecortex; or (iv) multiple sclerosis, the pre-selected sub-population of cells being brain oligodendrocytes.
  • Thyrogiobuiin Thyroid cells Hypothyroidism Pichon et al. (1994) Biochem J 298.537-41
  • HSV Herpes simplex virus
  • tk thymidine kinase gene
  • neo gene operably linked to a promoter which is active only in dopamine-containing neurones, e.g. that controlling expression of tyrosine hydroxylase (see e.g. that described by Harrington et al. (1987) Nucl. Acids Res. 15:2363).
  • the construct is then cloned into the appropriate cloning site of a retroviral vector, and used to transfect an amphotropic retroviral packaging cell line (e.g. f-crip (for review see Molecular Virology: A Practical Approach (Eds. AJ Davison & RM Elliott) IRL Press, 1993).
  • Tissue is dissected from embryonic (approximately 5-8 weeks of gestation) human ventral mesencephalon and grown in dissociated culture.
  • the dopaminergic precursor cells are induced to replicate, by application of fibroblast growth factor (Mayer et al. (1993) Neuroscience 56:389), epidermal growth factor (Reynolds & Weiss (1992) Science 255:1707) or by oncogene transduction (Stringer et al. (1994) Brain Res. 79:267).
  • the cultured cells are transduced with the retrovirally-packaged selectable markers, and the cultures allowed to expand. When sufficient numbers of cells are produced, the cultures are incubated under conditions leading to cessation of neuronal division.
  • the cultures are then treated with geneticin to eliminate non-transduced cells as well as transduced cells not expressing tyrosine hydroxylase, but leaving transduced, tyrosine hydroxylase-containing neurones.
  • Example 2 Preparation of a homogeneous culture of human oligodendrocvtes
  • HSV Herpes simplex virus
  • tk thymidine kinase gene
  • neo gene operably linked to a promoter which is active only in oligodendrocytes, that controlling expression of the oligodendrocyte-specific enzyme galactocerebrosidase.
  • the construct is virally packaged as in Example 1.
  • a virus such as adenovirus could alternatively be used.
  • Tiossue from embryonic or adult brain is dissected and grown in dissociated culture. If necessary, cell replication is induced (for example by using cells from HS2ts6 mice (Noble et al.
  • the cells are transduced with the genes coding for the positive selectable marker linked to, for example, the galactocerebrosidase promoter, and for the negative selectable marker linked to a constitutively active promoter, such as cytomegalovirus.
  • Cell selection is obtained as in Example 1, yielding pure populations of oligodendrocytes.
  • Example 3 Preparation of a homogeneous culture of essentially normal human dorsal root ganglion cells expressing calcitonin gene related peptide
  • Neurones from dorsal root ganglia can be grown in vivo using either embryonic, neonatal or adult tissue as a source material.
  • the mixed cell population will be grown on, for example, a background layer of e.g. previously prepared neomycin resistant non-neuronal cells to provide trophic support (Brenneman et al. (1987) J. Cell Biol. 104:1603).
  • the DRG cells are transfected using adenoviral technology with a neo gene linked operably to the promoter for calcitonin gene related peptide (CGRP) expression.
  • CGRP calcitonin gene related peptide
  • retroviral particles comprising a construct (tsA58) incorporating a resistance marker to geneticin (G418 r ) linked to an SV40T promoter were added to the medium together wtih 0.8 ⁇ g/ml polybrene. After lh the culture medium was replaced with fresh medium. After 5 days, geneticin was added to the culture medium (0.4 mg/ml) for a further 10 days to eradicate cells which had not incorporated the retroviral vector.
  • clusters of human neural precursor cells could be found from all of the areas listed above which were able to replicate in the FGF-containing medium and which were also geneticin resistant. All exhibited a neuronal phenotype (they were for example neurone specific enolase positive) .
  • the construct can include a selection marker such as geneticin resistance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A method for selectively culturing a pre-selected sub-population of cells from a heterogeneous cell population in vitro, comprises the steps of: (a) introducing a selectable marker (e.g. a positive and/or negative selectable marker) into the heterogeneous cell population, which marker is subject to differential expression/activity in the pre-selected sub-population; and (b) selectively culturing the pre-selected sub-population on the basis of the differential expression/activity therein of the selectable marker.

Description

CELL CULTURE METHOD
The present invention relates to cell culture methods, and in particular to cell culture methods for the production of an essentially homogeneous population of cells (for example neuronal cells) in vitro. The invention also relates to neural cells (e.g. human neural cells) having introduced therein a selectable marker (e.g. a positive and/or negative selectable marker) .
The central nervous sytem is presently the subject of intense research, but its enormous complexity at the cellular level has militated against a full understanding of its function. While increasingly selective methods of labelling specific sub-populations of neural cells ex vivo (such as immunostaining, in situ hybridization histochemistry etc.) have been developed, the separation and purification of such sub-populations as living cells presents severe difficulties.
Various approahes have been adopted to address this problem. For example, techniques such as differential centrifugation have been used to enrich for specific neural cell phenotypes. Other methods have been based on the use of fluorescent cell type-specific substrates to label sub- populations of cells,or the use of fluorescent tracer dyes injected into a specific termination area of a given set of neurones (Schaffner et al. (1987) J. Neuroscience 7:3088). In each case, separation of labelled from unlabelled cells is by fluorescence-activated cell sorting (FACS) .
Another method is based upon the identification of extracellular membrane-bound markers specific for a given cell type (Urakami & Chiu (1990) J. Neuroscience 10:620). Here, separation in this example is achieved by panning the mixed cell population on an adherent antibody layer to produce cell-antibody complexes from which the cells of interest can later be dissociated for further study.
According to another known method, progenitor cells which give rise to specific cell populations are immortalized by oncogene transduction or by the sub-culturing of spontaneous cell outgrowths.
With the exception, perhaps, of the precursor cell immortalization technique, most of these methods have not acquired widespread application. This is partly due to the enormous heterogeneity of phenotypes within the central nervous system, such that the markers and the separation techniques utilised have to be extremely specific to avoid cross-reacting with unwanted cell types.
Secondly, the degree of purification required to obtain homogeneity is often two or more orders of magnitude: such an enrichment is too great for FACS or panning, the result being a degree of contamination.
Thirdly, the availability of sufficiently abundant, yet adequately specific, extracellular markers which are also common to the better characterized neural cell groups (e.g. dopaminergic cells, or glutamatergic cells) is limited.
Moreover, most of these known enrichment techniques require relatively immature neural cells, to prevent their destruction during the procedure.
Finally, these considerations are even more restrictive for human neural cells because of the difficulties in obtaining suitable amounts of fresh human brain tissue.
The present invention provides a method for selectively culturing a pre-selected sub-population of cells from a heterogenous population in vitro, comprising the steps of: (a) introducing a selectable marker (e.g. a positive and/or negative selectable marker) into the heterogenous cell population, which marker is subject to differential expression/activity in the pre-selected sub-population; and (b) selectively culturing the pre-selected sub-population on the basis of the differential expression/activity therein of the selectable marker.
The pre-selected sub-population of cells may be an essentially homogeneous population of cells of a particular cell type or cell class. For example, the pre-selected sub-population may be a particular class of neural cells. In the case of neural cells, the pre-selected population may be selected on the basis of transmitter characteristics, e.g. dopamine- or acetylcholine-containing neurones may be selectively cultured according to the method of the invention.
The selectable marker need not be introduced into every cell making up the heterogenous cell population: for most purposes it is sufficient if a significant proportion of the cells receive the selectable marker.
Preferably, however, the selectable marker(s) are introduced into a large proportion (for example essentially all) of the heterogenous cell population. As explained herein, the method of the invention finds particular application in the selective culture of particular classes of essentially normal neural cells. However, the method of the present invention is of general application and may be used to selectively culture other sub-populations of cells.
It is known in the art that mammalian neural cells can be transduced with heterologous genetic material. Many methods exist for transducing eukaryotic and other cells, but the characteristics of neural cells are such that natural methods of transfection are presently the most useful (Miller (1992) Nature 357:455). Thus, transduction with virally-packaged genetic material, for example, is not only more efficient, but also results in a lower neural cell mortality during the actual process than does, for example, calcium phosphate precipitation, electroporation, microprojectile bombardment or microinjection. Transduction of mammalian neural cells from the central nervous system both in vivo (Culver et al. (1992) Science 256:1550) and in vitro (Stringer & Foster (1994) Brain Res 79:267) has been described.
The genetic material that can be introduced into living cells may include both positive and negative selectable markers. A positive selectable marker is one that permits survival of the transduced cell under conditions which would kill cells not expressing the selectable phenotype. A negative selectable marker confers sensitivity on the cells which express it, such that they are destroyed under conditions which are relatively innocuous to other cells.
A wide variety of selectable markers is available. Genes that are widely applied as positive selectable markers include the bacterial neomycin phosphotransferase (neo; Colbere-Garapin et al. (1981) J. Mol. Biol. 150:1), hygromycin phosphotransferase (hph; Santerre et al. (1984) Gene 30:147) and xanthineguanine phosphoribosyl transferase (gpt; Mulligan & Berg (1981) Proc. Natl. Acad. Sci. USA 78:2072).
Also used as positive selectable markers are the herpes simplex virus type 1 thymidine kinase (HSV-1 TK; Wigler et al. (1977) Cell 11:223), adenine phosphoribosyl transferase (APRT; Wigler et al. (1979) Proc. Natl. Acad. Sci., USA 76:1373) and hypoxanthine phosphoribosyl transferase (HPRT; Jolly et al. (1983) Proc. Natl. Acad. Sci., USA 80:477). These latter markers must be used in cells having a particular mutant genotype (viz. one which leads to a deficiency in the gene product on which the selection is based) .
Preferred negative selectable markers include genes encoding products involved in programmed cell death (apoptosis), for example the gene for p53. Such negative selectable markers may be activated by inducing the expression of the gene in question (for example by use of a tetracycline-responsive promoter, as described infra) . The use of genes encoding products involved in apoptosis has the advantage that transient expression (in many cases 30 minutes or less) of the gene may be sufficient to commit the cell to death, permitting reliable and very stringent negative selection.
Some of the aforementioned genes also confer negative as well as positive selectable phenotypes. They include the HSV-1, APRT, HPRT and gpt genes. These genes encode enzymes which can catalyze the conversion of certain nucleoside or purine analogues to cytotoxic intermediates. For example, the nucleoside analogue ganciclovir (GCV) is a good substrate for the HSV-1 thy idine kinase, but a poor substrate for the natural thymidine kinase found in mammalian cells. Consequently, GCV can be used for efficient negative selection against cells expressing the HSV-1 TK gene (St. Clair et al. (1987) Antimicrob. Agents Chemotherap. 31:844).
Xanthineguanine phosphoribosyl transferase can be used for both positive and negative selection which expressed in wild type cells (Besnard et al. (1987) Mol. Cell Biol. 7:4139). Cytosine deaminase can also be used as a negative selection marker, converting the innocuous 5-fluorocytosine to the cytotoxic 5-fluorouracil (Polak & Scholer (1976) Chemotherapy (Basel) 21:113).
Selectable markers are usually used in both prokaryotic and eukaryotic genetic engineering to permit the recovery from a mixed population of cells those which have undergone a rare genetic change. For instance, they can be used in physical association with another gene which encodes a product of interest to select cells which have taken up that other gene along with the selectable marker. As an example, the neo gene has been used to monitor genetically modified cells taken from patient samples after gene therapy has taken place.
It has also been proposed to use negative selectable markers as a safety device in gene therapy (Lupton et al.
(1991) Mol. Cell Biol. 11:3374). Many gene therapies involve the removal of somatic cells from the patient, the introduction therein of a therapeutic gene (the expression of which repairs a biochemical lesion) , followed by reintroduction of the cells into the patient. Since the reintroduced genetically modified cells may ultimately prove deleterious to the health of the patient (for example, if they prove to be immunologically incompatible or become malignant), a negative selectable marker may be introduced along with the therapeutic gene to permit (if necessary) subsequent selective elimination of the genetically modified cells.
A number of vectors bearing positive or negative selectable markers have been made and are readily available to those skilled in the art (for review see Miller (1992) Nature 357:455). Others may be readily assembled using standard gene cloning techniques.
The method of the invention can include the prior induction of replication in mixed populations of embryonic neural cells, using supplements to the culture medium such as epidermal growth factor or fibroblast growth factor, or by prior transfection with immortalizing oncogenes, to elicit such replication. Alternatively, non-expanding cell cultures can be used. Preferably, at an early stage after plating, the cells are transduced with a positive selectable marker and a negative selectable marker, both linked operably to an expression element. The expression element may be specific for a given central nervous system region, a given neural cell type, or a specific sub-population of neurones. After the cultures have reached the required level of expansion, the cells may be allowed, at least partially, to differentiate. The appropriate drug can then be applied, such that non- transduced cells and those transduced cells without the active specific expression element are eliminated, while transduced cells with the active element (which leads to the expression of the downstream selectable markers) will be resistant.
By way of example only, the expression elements for use in the invention may be selected from: promoters and/or enhancers which are specifically active in: (i) dopaminergic, serotoninergic, GABAergic, cholinergic or peptidergic neurones, or sub-populations thereof; (ii) Schwann cells, oligodendrocytes, astroycytes, microglia and sub-populations thereof; (iii) particular stages of embryogenesis and (iv) other specific non-neural tissues. Particularly preferred for use in the present invention are the tetracycline-responsive promoters described in e.g. Furth et al. (1994) PNAS USA (Vol. 91, pp. 9302-9306). Such promoters can be used as an element in a tetracyclin- responsive regulatory system to effect temporal and/or spatial control of gene expression in vivo.
Alternatively, they may be selected from promoters and/or enhancers which direct the transcription of genes for: (i) neurotransmitter-specific receptors; (ii) ion channels; (iii) receptors involved in ion-channel gating, (iv) cytokines, growth factors and hormones and (v) any substance that is specifically produced and secreted in a paracrine, autocrine or endocrine fashion. For examples, see Table 1.
The invention provides a method of culturing human and other mammalian cells (e.g. neural cells) and, by selecting for a sub-population of cells on the basis of the genetic material contained within them, producing homogeneous cultures of a single cell type.
Such cultures can be put to a variety of uses including basic electrophysiological, neurochemical and developmental experimentation. In addition, the purified neural cell populations will be useful in more clinically applied studies, such as assessment of the feasibility of transplantation to alleviate the symptoms of central nervous sytem degenerative disease, and find application in various forms of therapy, prophylaxis and diagnosis.
Such diseases include: (i) Parkinson's disease or parkinsonism, the pre-selected sub-population of cells being dopaminergic neurones of the substantia nigra; (ii) Huntington's disease, the pre-selected sub-population of cells being neural cells of the striatum; (iii) Alzheimer's disease, the pre-selected sub-populations of cells being acetylcholine-, serotonin-, and/or noradrenaline-containing neurones associated with the neo- and palaecortex; or (iv) multiple sclerosis, the pre-selected sub-population of cells being brain oligodendrocytes.
TABLE 1
Promoter Tissue/cell type Application Reference
Tyrosinβ Catβcholaminergic Alzheimer's Stacho ick et ai. (1994) hydroxylase neurones Parkinson's Mol Brain Res 22.309-19
TSH receptor Thyroid ceils Hypothyroidism Ikuyama & Nakata (1994) Jap J Clin Med 52.962-8
BSF1 GABAergic neurones Epilepsy otejlek et al. (1994) J Biol Cham 269.15265-73
Human dopamtπe Noradrenaline neurones Alzheimer's Hoyle et al. (1994) J β-hydroxylase Neurosci 14,2455-63
Thyrogiobuiin Thyroid cells Hypothyroidism Pichon et al. (1994) Biochem J 298.537-41
Serotonin 2- Glial ceils in seroton- Neurodegeneraϋve Ding et al. (1994) Mol receptor inergic projection areas diseases Brain Res 20.181 -91
CD4 receptor CD4 expressing T- AIDS Nakayama et ai. (1993) lymphocytes Int Immunol 5.817-24
Human choline Acβtylcholme neurones Alzheimer's Li et al. (1993) Neuro- acetyl transferasβ Motoneurone disease chem Res 18.271-5 Example 1: Preparation of a homogeneous culture of human dopaminergic neurones
The Herpes simplex virus (HSV) thymidine kinase gene (tk) and the neo gene are operably linked to a promoter which is active only in dopamine-containing neurones, e.g. that controlling expression of tyrosine hydroxylase (see e.g. that described by Harrington et al. (1987) Nucl. Acids Res. 15:2363). The construct is then cloned into the appropriate cloning site of a retroviral vector, and used to transfect an amphotropic retroviral packaging cell line (e.g. f-crip (for review see Molecular Virology: A Practical Approach (Eds. AJ Davison & RM Elliott) IRL Press, 1993).
Tissue is dissected from embryonic (approximately 5-8 weeks of gestation) human ventral mesencephalon and grown in dissociated culture. The dopaminergic precursor cells are induced to replicate, by application of fibroblast growth factor (Mayer et al. (1993) Neuroscience 56:389), epidermal growth factor (Reynolds & Weiss (1992) Science 255:1707) or by oncogene transduction (Stringer et al. (1994) Brain Res. 79:267). Shortly after plating, the cultured cells are transduced with the retrovirally-packaged selectable markers, and the cultures allowed to expand. When sufficient numbers of cells are produced, the cultures are incubated under conditions leading to cessation of neuronal division. The cultures are then treated with geneticin to eliminate non-transduced cells as well as transduced cells not expressing tyrosine hydroxylase, but leaving transduced, tyrosine hydroxylase-containing neurones.
Example 2: Preparation of a homogeneous culture of human oligodendrocvtes
The Herpes simplex virus (HSV) thymidine kinase gene (tk) and the neo gene are operably linked to a promoter which is active only in oligodendrocytes, that controlling expression of the oligodendrocyte-specific enzyme galactocerebrosidase. The construct is virally packaged as in Example 1. A virus such as adenovirus could alternatively be used. Tiossue from embryonic or adult brain is dissected and grown in dissociated culture. If necessary, cell replication is induced (for example by using cells from HS2ts6 mice (Noble et al. (1991) WO 91/13150), and shortly after plating, the cells are transduced with the genes coding for the positive selectable marker linked to, for example, the galactocerebrosidase promoter, and for the negative selectable marker linked to a constitutively active promoter, such as cytomegalovirus. Cell selection is obtained as in Example 1, yielding pure populations of oligodendrocytes.
Example 3: Preparation of a homogeneous culture of essentially normal human dorsal root ganglion cells expressing calcitonin gene related peptide
Neurones from dorsal root ganglia (DRG) can be grown in vivo using either embryonic, neonatal or adult tissue as a source material. The mixed cell population will be grown on, for example, a background layer of e.g. previously prepared neomycin resistant non-neuronal cells to provide trophic support (Brenneman et al. (1987) J. Cell Biol. 104:1603). The DRG cells are transfected using adenoviral technology with a neo gene linked operably to the promoter for calcitonin gene related peptide (CGRP) expression. After several days to allow activation of the promoter and thereby induction of neo expression, DRG cells not actively expressing neo will be destroyed by application of neomycin. The result will be a pure population of differentiated CGRP-positive neurones from the human DRG, for use in vitro. Example 4: Transduction of neural cells
Primary cells from the foetal (at week 8 of gestation) human cortex, striatum, hypothalamus, mesencephalon, raphe complex, medulla oblongata and ventral horn of the spinal cord were separately plated onto gelatin/poly-L-lysine coated flasks. The medium was a mixture of DMEM/Ham's F12 (1:1) containing penicillin/streptomycin, L-glutamine (2mM) and a modified stock solution (Bottenstein and Sato, PNAS 76(1979)514-517; Romijn et al., J. Neurophysiol. 40(1981)1132-1150) containing basic fibroblast growth factor (5ng/ml).
Once the cells had adhered, retroviral particles comprising a construct (tsA58) incorporating a resistance marker to geneticin (G418r) linked to an SV40T promoter were added to the medium together wtih 0.8 μg/ml polybrene. After lh the culture medium was replaced with fresh medium. After 5 days, geneticin was added to the culture medium (0.4 mg/ml) for a further 10 days to eradicate cells which had not incorporated the retroviral vector.
After 15 to 20 days, clusters of human neural precursor cells could be found from all of the areas listed above which were able to replicate in the FGF-containing medium and which were also geneticin resistant. All exhibited a neuronal phenotype (they were for example neurone specific enolase positive) .
Thus, it is possible to transduce stably human neural cells from a variety of areas of the central nervous system with retrovirally packaged gene constructs. Secondly, the construct can include a selection marker such as geneticin resistance.

Claims

1. A method for selectively culturing a pre-selected sub- population of cells from a heterogeneous cell population in vitro, comprising the steps of:
(a) introducing a selectable marker (e.g. a positive and/or negative selectable marker) into the heterogeneous cell population, which marker is subject to differential expression/activity in the pre-selected sub-population; and
(b) selectively culturing the pre-selected sub- population on the basis of the differential expression/activity therein of the selectable marker.
2. The method of claim 1 wherein the selectable marker comprises a negative selectable marker not subject to differential expression/activity in the pre-selected sub-population (e.g. a constitutively-expressed negative selectable marker) .
3. The method of claim 1 or claim 2 wherein the cells are neural cells, for example neurones.
4. The method according to any one of the preceding claims wherein the heterogeneous cell population is a primary cell culture, for example a human (e.g. foetal) neural primary cell culture, for example comprising neural stem/precursor cells.
5. The method according to any one of the preceding claims wherein in step (b) the pre-selected sub- population is selectively cultured on the basis of: (i) the expression/activity therein of a positive selectable marker, or (ii) the lack of expression/ activity therein of a negative selectable marker.
6. The method of any one of the preceding claims wherein step (a) the selectable marker is introduced by retroviral transduction, for example with a recombinant amphotopically packaged retrovirus.
7. The method of any one of the preceding claims wherein the selectable marker is:
(i) a positive selectable marker selected from neomycin phosphotransferase, hygromycin phosphotransferase, xaπthineguanine phosphoribosyl transferase, the Herpes simplex virus type 1 thymidine kinase, adenine phosphoribosyltransferase and hypoxanthine phosphoribosyltransferase, and/or (ii) a negative selectable marker selected from Herpes simplex virus type 1 thymidine kinase, adenine phosphoribosyltransferase, hygromycin phosphotransferase, cytosine dea inase and hypoxanthine phosphoribosyltransferase.
8. The method according to any one of the preceding claims wherein the selectable marker is operably linked to an expression element or elements, for example a regulatable expression element or elements, e.g. a tissue- or cell-specific expression element or elements.
9. The method according to claim 7 wherein the expression element is selected from:
(A) promoters and/or enhancers which are specifically active in: (i) dopaminergic, serotoninergic, GABAergic, cholinergic or peptidergic neurones and sub-populations thereof; (ii) Schwann cells, oligodendrocytes, astrocytes microglia and sub-populations thereof; (iii) particular stages of embryogenesis; (iv) the endocrine glands, lungs, muscles, gonads, intestines, skeletal tissue or part or parts thereof; (v) epithelial, fibroblast, fat, mast mesenchymal or parenchymal cells, and (vi) components of the blood system (e.g. T- lymphocytes, B-lymphocytes and macrophages) ; or (B) promoters/enhancers which direct the transcription of genes for: (i) neurotransmitter- specific receptors; (ii) ion channels; (iii) receptors involved in ion-channel gating and (iv) cytokines, growth factors and hormones.
10. The method according to any one of the preceding claims wherein step (b) the pre-selected sub- population is selectively cultured by incubating the cells with a selective agent or drug, for example neomycin or geneticin.
11. The method according to any one of the preceding claims wherein the heterogeneous cell population is produced by the preliminary step of in vitro cell culture in the presence of a growth factor (for example epithelial growth factor or fibroblast growth factor) and/or cells providing trophic support.
12. The method according to any one of the preceding claims wherein the heterogeneous population of step (a) is expanded and/or induced to differentiate before or after the introduction of a selectable marker.
13. A sub-population of cells produced by the method of any one of the preceding claims.
14. The cells of claim 13, for use in therapy, prophylaxis or diagnosis.
15. Use of the cells of claim 13 for the manufacture of a medicament for use in therapy, prophylaxis or diagnosis.
16. The cells of claim 14 or the use of claim 15 wherein the therapy is transplantation therapy.
17. The cells or use of claim 16 wherein the transplantation therapy is for the treatment of: (i)
Parkinson's disease and/or parkinsonism, the pre¬ selected sub-population of cells being dopaminergic neurones from the substantia nigra; (ii) Huntington's chorea, the pre-selected sub-population of cells being neual cells of the striatum; (iii) Alzheimer's disease, the pre-selected sub-population of cells being acetylcholine-containing, serotonin-containing and/or noradrenaline-containing neurones associated with palaeo- and neocortex; (iv) amyotrophic lateral sclerosis, the pre-selected sub-population of cells being motoneurones from the spinal cord; or (v) multiple sclerosis, the pre-selected sub-population of cells being brain oligodendrocytes.
18. Neural cells (e.g. a human neural cells) having introduced therein one or more selectable markers (e.g. a positive and/or negative selectable marker) .
19. Cells according to claim 18 wherein at least one selectable marker is subject to regulation.
20. Cells according to claim 18 or 19 wherein at least one selectable marker is a constitutively expressed negative selectable marker.
21. Cells according to any one of claims 18-20 wherein the selectable marker(s) are introduced by transfection or infection (e.g. with a retroviral vector) .
22. Cells according to any one of claims 18-21 for use in therapy (for example transplantation therapy, e.g. as defined in claim 17), prophylaxis or diagnosis.
23. A graft or tissue implant comprising the cells of claim 13 or any one of claims 18-22.
EP96907597A 1995-03-21 1996-03-20 Cell culture method Withdrawn EP0815206A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9505663 1995-03-21
GBGB9505663.6A GB9505663D0 (en) 1995-03-21 1995-03-21 Genetically modified neural cells
PCT/GB1996/000671 WO1996029395A1 (en) 1995-03-21 1996-03-20 Cell culture method

Publications (1)

Publication Number Publication Date
EP0815206A1 true EP0815206A1 (en) 1998-01-07

Family

ID=10771558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96907597A Withdrawn EP0815206A1 (en) 1995-03-21 1996-03-20 Cell culture method

Country Status (10)

Country Link
EP (1) EP0815206A1 (en)
JP (1) JPH11502702A (en)
KR (1) KR19980703205A (en)
AU (1) AU5116596A (en)
CA (1) CA2214385A1 (en)
CZ (1) CZ295997A3 (en)
GB (1) GB9505663D0 (en)
HU (1) HUP9802640A3 (en)
NZ (1) NZ304076A (en)
WO (1) WO1996029395A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807935D0 (en) * 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US6482937B1 (en) * 1997-10-09 2002-11-19 Biotransplant, Inc. Porcine Oct-4 promoter
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
DK1740945T3 (en) 2004-04-07 2019-01-21 Ncardia Ag KKE-INVASIVE, IN-VITRO FUNCTIONAL TISSUE TEST SYSTEMS
JP4814875B2 (en) 2004-05-11 2011-11-16 アキシオジェネシス エージー Assay for drug discovery based on in vitro differentiated cells
US20110223671A1 (en) * 2008-09-30 2011-09-15 Novozymes, Inc. Methods for using positively and negatively selectable genes in a filamentous fungal cell
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6612227B2 (en) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
EP3122866B1 (en) 2014-03-25 2019-11-20 Terumo BCT, Inc. Passive replacement of media
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
JP7034949B2 (en) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド Cell proliferation
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN110612344B (en) 2017-03-31 2023-09-12 泰尔茂比司特公司 cell expansion
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070243A (en) * 1976-08-30 1978-01-24 University Of Illinois Foundation Method for distinguishing subpopulations in a population of morphologically indistinguishable cells
CA1228025A (en) * 1983-05-20 1987-10-13 Paul I. Terasaki Method and composition for isolating white cell elements
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
US5514552A (en) * 1993-04-30 1996-05-07 Arch Development Corporation Hybrid neuronal cell lines compositions and methods
GB9422236D0 (en) * 1994-11-03 1994-12-21 Stringer Bradley M J Transgenic organisms and their uses
GB9422643D0 (en) * 1994-11-08 1995-01-04 Stringer Bradley M J Neural cell lines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9629395A1 *

Also Published As

Publication number Publication date
HUP9802640A3 (en) 1999-04-28
WO1996029395A1 (en) 1996-09-26
AU5116596A (en) 1996-10-08
CZ295997A3 (en) 1998-01-14
HUP9802640A2 (en) 1999-03-29
KR19980703205A (en) 1998-10-15
GB9505663D0 (en) 1995-05-10
JPH11502702A (en) 1999-03-09
MX9707195A (en) 1997-11-29
NZ304076A (en) 2001-01-26
CA2214385A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
US6432711B1 (en) Embryonic stem cells capable of differentiating into desired cell lines
EP0815206A1 (en) Cell culture method
Anklesaria et al. Cell-cell adhesion mediated by binding of membrane-anchored transforming growth factor alpha to epidermal growth factor receptors promotes cell proliferation.
US7078230B2 (en) Adipose tissue-derived stromal cell that expresses characteristics of a neuronal cell
JP4012688B2 (en) Genetically modified CD34-negative adherent growing stem cells and their use in gene therapy
WO1999064566A2 (en) In vitro maintenance of hematopoietic stem cells
Wekerle et al. Intrathymic pathogenesis of myasthenia gravis: transient expression of acetylcholine receptors on thymus‐derived myogenic cells
EP0457856A4 (en) Isolation growth and differentiation of human muscle cells
Pollack et al. Response of malignant glioma cell lines to epidermal growth factor and platelet-derived growth factor in a serum-free medium
US20050214941A1 (en) Expansion of neural stem cells with LIF
Brenner Gene marking
Bolin et al. Isolation of activated adult Schwann cells and a spontaneously immortal Schwann cell clone
EP2024493B1 (en) Methods of selecting stem cells and uses thereof
Gage et al. Grafting genetically modified cells to the brain: conceptual and technical issues
Eves et al. Conditional immortalization of neuronal cells from postmitotic cultures and adult CNS
US20060233769A1 (en) Established cell line of microglia
AU750828B2 (en) Cell culture method
Baumann et al. Glial biology and disorders
MXPA97007195A (en) Celu culture method
KR20110090810A (en) Method for proliferating stem cells using genes activating notch signaling
WO1994001129A1 (en) Use of myoblasts for sustained delivery of gene products
US20030109037A1 (en) Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
EP1799236A2 (en) Liver stromal cells for prevention and treatment of immune responses in transplantation
WO2008027848A2 (en) Transcription factors for differentiation of adult human olfactory progenitor cells
CN115803436A (en) Novel transplanted cells with reduced immunogenicity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLFACTORS PLC

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STRINGER, BRADLEY MICHAEL JOHN, DR.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLFACTORS PLC

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELLFACTORS PLC

17Q First examination report despatched

Effective date: 20010731

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20051129